Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates

Journal of Antimicrobial Chemotherapy

Volumn 39, Issue SUPPL. B, 1997, Pages 29-34

  Cunha, Burke A ^a,b   Qadri, S M Hussain ^c   Ueno, Y ^c   Walters, E A ^c   Domenico, P ^a,b  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; AMINOGLYCOSIDE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; NORFLOXACIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ACINETOBACTER CALCOACETICUS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DILUTION; ENTEROBACTERIACEAE; ENTEROCOCCUS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HOSPITAL INFECTION; HUMAN; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS;

EID: 0030877795     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/39.suppl_2.29     Document Type: Article

References (18)

1. Gootz, T. D., Brighty, K. E., Anderson, M. R., Schmieder, B. J., Haskeil, S. L, Sutcliffe, J. A. et al. (1994). In vitro activity of CP99,219, a novel 7-(3-azabicylo[3.1.0]hexyl) naphthyridone antimicrobial. Diagnostic Microbiology and Infectious Disease 19, 235-43.
2. Hooper, D. C. & Wolfson, J. S. (1991). Fluoroquinolone antimicrobial agents. New England Journal of Medicine 324, 384-94.
3. Paton, J. H. & Reeves, D. S. (1988). Fluoroquinolone antibiotics: microbiology, pharmacokinetics and clinical use. Drugs 36, 193-228.
4. Siporin, C. (1989). The evolution of fluorinated quinolones: pharmacology, microbiological activity, clinical uses, and toxicities. Annual Review of Microbiology 43, 601-27.
5. Wolfson, J. S. & Hooper, D. C. (1989). Fluoroquinolone antimicrobial agents. Clinical Microbiology Reviews 2, 378-424.
6. Murray, P. R., Baron, M. J., Pfaller, M. A., Tenover, F. C. & Yolken, R. H., Eds (1995). Manual of Clinical Microbiology, 6th Edn. American Society for Microbiology, Washington, DC.
7. National Committee for Clinical Laboratory Standards. (1993). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Third Edition. Approved Standard M7-A3. NCCLS, Villanova, PA.
8. Haley, R. W., Culver, D. H., White, J. W., Morgan, W. M. & Emori, T. G. (1985). The nationwide nosocomial infection rate: a new need for vital statistics. American Journal of Epidemiology 121, 159-67.
9. Ayliffe, G. A. J., Collins, B. J. & Taylor, L. J. (1990). HospitalAcquired Infections: Principles and Prevention, 2nd edn, pp. 1-6. Wright, London.
10. Farrar, W. E. (1985). Antibiotic resistance in developing countries. Journal of Infectious Diseases 152, 1103-6.
11. Murray, B. E., Alvarado, T., Vorachit, M., Jayanetra, P., Levine, M. M. et al. (1985). Increasing resistance to trimethoprimsulfamethoxazole among isolates of Escherichia coli in developing countries. Journal of Infectious Diseases 152, 1107-13.
12. Qadri, S. M. H., Huber, T. W., Lee, G. C. & al-Hajjar, S. (1994), Antimicrobial resistance of bacterial pathogens at two tertiary-care centers, in Riyadh & Texas. Texas Medicine 90, 59-62.
13. Shibl, A. M. (1992). Incidence of β-lactamase production among out patient clinical isolates in Middle Eastern countries and their antibiotic susceptibilities. Chemotherapy (Basle) 38 324-9.
14. Qadri, S. M. H., Cunha, B. A., Ueno, Y., Kayes, S. & Postle, A. G. (1995). Etiology of nosocomial infections and the susceptibility of nosocomial pathogens to imipenem and other antimicrobial agents at a tertiary care referral hospital. Current Therapeutic Research 56, 746-755.
15. Neu, H. C. & Chin, N. X. (1994). In-vitro activity of the new fluoroquinolone CP-99,219. Antimicrobial Agents and Chemotherapy 38, 2615-22.
16. Eliopoulos, G. M., Klimm, K., Eliopoulos, C. T., Ferraro, M. J. & Moellering, R. C. (1993). In vitro activity of CP-99-219, a new fluoroquinolone, against clinical isolates of Gram-positive bacteria. Antimicrobial Agents and Chemotherapy 37, 366-70.
17. Gooding, B. B. & Jones, R. N. (1993). In-vitro antimicrobial , activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrobial Agents and Chemotherapy 37, 349-53.
18. Spangler, S. K., Jacobs, M. R. & Appelbaum, P. C. (1994). Activity of CP-99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin and piperacillintazobactam against 489 anaerobes. Antimicrobial Agents and Chemotherapy 38, 2471-6.